Biotech Investors & VC Firms in Europe
832 firms in this list, with a median first check of $500K. 187 of them lead rounds. Generated from verified public data and updated continuously.
Cloud Health Euroventures
NewarkPre-Seed–Series A$100K – $1M
21 people
Expon Capital
LuxembourgPre-Seed–Growth$550K – $1.6M
6 people
Big Pi Ventures
AthensPre-Seed–Growth$540K – $3.2M
17 people
Delin Ventures
LondonPre-Seed–Series A$216K – $2.2M
18 people
NOON Ventures
CopenhagenSeed–Series A$500K – $10M
18 people
GU Ventures AB
GöteborgSeed–Series A
28 people
Creathor Ventures
Bad HomburgSeed–Late Stage$540K – $10.8M
Synthesis Capital
LondonSeed–Series C
18 people
Bioqube Ventures
BrusselsPre-Seed–Late Stage$108K – $6.5M
17 people
Brightlands Venture Partners
GeleenSeed–Series B$540K – $2.2M
14 people
Senovo
MunichSeed–Late Stage$1.1M – $5.4M
7 people
V-Bio Ventures
GhentSeed–Growth$270K – $2.2M
13 people
Shackleton Ventures Ltd.
LondonSeed–Series A$952.5K – $25.4M
6 people
Martlet Capital
CambridgePre-Seed–Series A$317.5K
8 people
Neva Sgr.
TurinSeries A–Growth
8 people
White Fund
LiègeSeed–Series B$2.2M – $5.4M
16 people
Zinc
LondonPre-Seed–Seed
16 people
NovaCapital
Seed–Late Stage
9 people
Blue Wire Capital
LondonPre-Seed–Series A$50K – $300K
5 people
Indico Capital Partners
LisbonSeed–Growth$250K – $10M
8 people
Innovation Fund sa/nv
SchaerbeekSeed–Series B$270K – $2.7M
17 people
Invivo Capital Partners
BarcelonaPre-Seed–Series A$2.2M – $4.3M
11 people
Mérieux Equity Partners
ParisSeed–Late Stage$3.2M – $86M
14 people
Bonitás Ventures
BudapestSeries A–Late Stage$540K – $4.3M
19 people
Related lists
Investors & VC Firms in North America (13808)Investors & VC Firms in United States (12951)Investors & VC Firms in Europe (5511)Crypto & Web3 Investors & VC Firms (4813)Investors & VC Firms in Global (4134)SaaS Investors & VC Firms (3860)AI & Machine Learning Investors & VC Firms (3764)Fintech Investors & VC Firms (3709)Investors & VC Firms in Asia-Pacific (3560)Healthtech Investors & VC Firms (3408)
Data sourced from public filings and firms' own websites — see our methodology.




































































































